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S U M M A R Y
Background: Old age, leucocytosis, hypoalbuminemia, and elevated creatinine have been
identified as risk factors for fulminant Clostridioides difficile infection (CDI). High ATLAS
scores have also been linked to fatal disease. The affiliated studies, however, involved
patients prescribed metronidazole - a regimen no longer standard of care. The variables
were thus reassessed in patients prescribed optimal therapy.
Methods: Adults hospitalized with CDI at University of Kentucky Medical Center were
retrospectively reviewed. Enrolled subjects were separated according to disease classi-
fication i.e. non-severe/severe versus fulminant CDI. Fulminant patients were further
subdivided into hypotensive persons responsive to fluid resuscitation, and those with
sequent shock, ileus, or megacolon. Following partition, the cohorts underwent correla-
tion analysis.
Findings: Forty-five subjects had non-severe/severe disease. Thirteen fulminant CDI
patients responded to fluid resuscitation. Seventeen fulminant CDI patients developed
shock, ileus, or megacolon. Median WBC counts, albumin values, and ATLAS scores varied
among the cohorts. Although WBC counts were similar among the fulminant subsets,
declining albumin values and increasing ATLAS scores mirrored disease worsening. Logistic
regression revealed albumin values < 20 g/L (odds ratio [OR] 3.91) and ATLAS scores  6
(OR 5.03) to predict critical illness in hypotensive persons.
Conclusion: Median WBC counts, albumin values, and ATLAS scores differed in patients
separated by CDI severity. A notable variance in albumin values and ATLAS scores between
fluid responsive fulminant disease and critical illness was moreover seen. The finding
suggests hypoalbuminemia and high ATLAS scores in hypotensive CDI patients may herald
shock, ileus, or megacolon.
ª 2021 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Clostridioides difficile is the leading infectious cause of
healthcare-associated diarrhea [1]. Risk factors for C. difficile
infection (CDI) include advanced age, prolonged hospital-
ization, and severe underlying illness [2]. The most widely
recognized modifiable risk factor, though, is antibiotic use. The
risk of disease increases up to 10-fold during antibiotic therapy
and CDI accounts for 15 to 25% of all episodes of antibiotic-
associated colitis [3,4].
Following fecal-oral transmission of C. difficile, some
patients become asymptomatic carriers of the organism. Oth-
ers incur a variety of CDI-related manifestations. Watery
diarrhea and abdominal pain predominate in uncomplicated
cases [5]. Progressive disease, however, can lead to fulminant
CDI e characterized by hypotension, shock, ileus, or toxic
megacolon. Life-saving colectomy is oftentimes needed in the
latter scenario [1].
Infectious Diseases Society of America (IDSA)/Society for
Healthcare Epidemiology of America (SHEA) criteria for disease
severity has long been defined by serumwhite blood cell counts
and creatinine levels. Previous IDSA/SHEA clinical practice
guidelines employed the classification to guide treatment.
Initial episodes of mild-to-moderate uncomplicated CDI called
for metronidazole while severe disease necessitated oral van-
comycin [6]. Several studies have since shown vancomycin to
be superior in cure and disease recurrence [7e10]. As a result,
present guidelines no longer support metronidazole mono-
therapy. Vancomycin or fidaxomicin is now considered the drug
of choice for uncomplicated CDI regardless of severity [1].
The standard antibiotic regimen for fulminant CDI continues
to be oral vancomycin plus intravenous metronidazole [1]. Even
with optimal therapy, though, fulminant CDI can prove fatal.
Mortality rates of 34e80% have been reported in patients with
fulminant disease [11]. Prior studies have found old age, leu-
cocytosis, hypoalbuminemia, and elevated creatinine to be risk
factors for fulminant CDI [12e15]. A study by Hernández-Garcı́a
et al. involving 102 CDI patients additionally revealed a 100%
mortality rate in the 4 persons whose ATLAS score was 8 [16].
However, several patients in the respective studies were
administered metronidazole alone. The variables were thus
reassessed in subjects prescribed contemporary therapy.
Methods
Study design and subject selection
Adult patients hospitalized with an initial episode of CDI
between 1st January 2018 and 30th June 2020 at University of
Kentucky Medical Center (UKMC) were identified. Those with
uncomplicated disease who received either oral vancomycin or
fidaxomicin, and fulminant CDI patients administered oral
vancomycin plus intravenous metronidazole underwent further
analysis. Persons with a history of recurrent CDI, irritable
bowel syndrome, inflammatory bowel disease, prior colonic
surgery, or chronic diarrhea were excluded. Those adminis-
tered laxatives 3 days prior to the onset of attributable CDI
symptoms, discharged against medical advice prior to com-
pletion of therapy, or had care withdrawn prematurely were
also excluded. No patients received fecal microbiota trans-
plantation, bezlotoxumab, rifaximin, or tigecycline.
Participants were divided into three groups. One group
contained non-severe/severe CDI patients. Fulminant CDI
patients constituted the other two groups and were separated
according to treatment needs. Hypotensive patients responsive
to fluid resuscitation constituted one subset. Hypotensive
patients who later developed shock, ileus, or megacolon
comprised the other subset.
Age, sex, comorbid conditions, inpatient medications, and
imaging results of subjects were recorded. White blood cell
counts, serum creatinine levels the day of CDI diagnosis (or
within one day of diagnosis if not available), and lattermost
obtained albumin values in the 5 days preceding CDI diagnosis
(or the day after if not available) were documented. Finally,
vital signs and pertinent patient signs/symptoms as per elec-
tronic medical record (EMR) documentation were noted.
Clinical data collection and definitions
Hemodynamically stable patients with unexplained acute
diarrhea (3 unformed stools over 24 hours) plus positive stool
C. difficile nucleic acid amplification test (NAAT) and toxin
enzyme immunoassay (EIA) results were diagnosed with
uncomplicated CDI. Those with a white blood cell count < 15 x
109 cells/litre and a serum creatinine level < 133 umol/L were
labelled as non-severe. Persons with a white blood cell count
15 x 109 cells/litre or a serum creatinine level  133 umol/L
were designated as severe.
Patients with positive C. difficile NAAT and toxin EIA results
who were hypotensive or suffering from shock, ileus, or meg-
acolon were diagnosed with fulminant CDI. Hypotension was
defined as a systolic blood pressure < 100 mm Hg or a mean
arterial pressure < 70 mm Hg while experiencing CDI-related
symptoms. Shock was defined as hypotension requiring vaso-
pressor agents. Instances of ileus and megacolon were diag-
nosed in persons with compatible clinical manifestations and
supportive radiographic or computed tomography imaging
findings. Patient deaths were accounted for if attributable to
CDI.
Charlson comorbidity index (CCI) and ATLAS score values
were calculated using conventional scoring methods [17,18].
Relevant medical conditions detailed in EMR documentation
determined patient CCI values. ATLAS scores incorporated
patient laboratory data according to timeline stipulations
detailed previously.
Treatment regimens
Oral vancomycin 125 mg 4 times daily or fidaxomicin 200 mg
twice daily was administered to patients with non-severe/
severe CDI. Those with fulminant disease received vancomy-
cin 500 mg 4 times daily either orally or by nasogastric tube plus
parenteral metronidazole 500 mg every 8 hours.
Statistical analysis
Data were analyzed using SAS version 9.4 (Cary, NC, USA). P-
values < 0.05 were considered significant. Descriptive sta-
tistics were conducted to describe the sample data with
means, standard deviations, medians, and interquartile ranges
for all continuous variable, plus frequencies and percentages
for all categorical variables. To examine relationships between
the study variables and the outcome, analysis of variance was
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conducted for continuous variables, and chi-square tests were
conducted for categorical variables. Due to sample size, the
two complicated groups were grouped together to create a
dichotomous outcome. Logistic regression was conducted to
obtain unadjusted and adjusted odds ratios. The adjusted
model only included variables that were significant at the 0.05
level.
Results
One hundred eighty-two CDI patients were identified during
the study period. Implementing exclusion criteria resulted in a
study population of 75 subjects. Forty-five patients were
uncomplicated, with 22 persons suffering from severe disease.
Thirty subjects had fulminant CDI. Thirteen patients responded
to fluid resuscitation. Seven persons suffered shock, 3 were
diagnosed with ileus, and 7 patients had megacolon. Four
patients with megacolon underwent colectomy (Figure 1).
A slight mean age difference was seen among the cohorts.
The disparity was not statistically significant, however. Ele-
vatedmedian creatinine levels were seen in all subsets. While a
mild worsening of renal function paralleled disease pro-
gression, the variance was not statistically significant. Of note,
4 persons with non-severe/severe CDI and 2 persons with ful-
minant CDI had dialysis-dependent chronic kidney disease at
the time of hospitalization. Their serum creatinine levels were
not incorporated into median computations. The median WBC
count of the non-severe/severe CDI group was within normal
Figure 1. Patient distribution.
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limits at 7.39 x 109 cells/litre. Both fulminant CDI subsets
exhibited elevated median WBC counts: 14 x 109 cells/litre in
patients responsive to fluid resuscitation and 14.9 x 109 cells/
litre in patients with shock, ileus, or megacolon. A stepwise
decline in albumin and increase in ATLAS score coincided with
disease progression. The finding was especially noteworthy in
fulminant CDI patients. Median albumin values fell from 24 g/L
in subjects with fluid responsive disease to 18 g/L in those with
shock, ileus, or megacolon. Median ATLAS scores rose from 5 in
persons with fluid responsive disease to 6 in those with shock,
ileus, or megacolon (Table I). Logistic regression revealed the
two variables to correlate with the development of critical
illness in hypotensive CDI patients. Specifically, albumin values
< 20 g/L (odds ratio [OR] 3.91; 95% confidence interval [CI] ¼
1.11e13.81) and ATLAS scores  6 (OR 5.03; 95% CI ¼
1.58e16.01) predicted ensuing shock, ileus, or megacolon after
covariate adjustment (Table II).
The possibility of pre-existing comorbidities impacting dis-
ease severity led us to compare median CCI values of the
cohorts. The decision was additionally influenced by Baiomi
et al. associating high CCI scores with CDI-related mortality
[19]. No statistically significant difference was seen.
CDI culminated in 7 deaths. All had fulminant disease with
accompanying shock, ileus, or megacolon. Only one of the
patients who expired had an ATLAS score  8. Furthermore,
two survivors (one belonging to the non-severe/severe group
and the other belonging to the fluid responsive fulminant CDI
group) had ATLAS scores  8.
Discussion
Fulminant CDI is a substantial cause of patient morbidity and
mortality. Early diagnosis is crucial in disease management and
minimizing poor outcomes [20]. Antibiotics along with aggres-
sive fluid resuscitation, electrolyte replacement, and nutri-
tional support are essential in hypotensive patients [21]. Even
with these measures, however, shock, ileus, or megacolon can
abruptly occur.
The potential for CDI patients to rapidly deteriorate
underscores the need for reliable prognostic markers. As
mentioned before, while several risk factors for fulminant CDI
have been identified, they were validated in subjects pre-
scribed substandard therapy. Upon reassessing the variables,
we found leucocytosis and hypoalbuminemia to correlate with
fulminant CDI. While ATLAS scores  8 were not inevitably
fatal, higher scores were associated with fulminant CDI as well.
Of more clinical importance was the relationship between the
latter two variables and spectrum of disease. Median WBC
counts doubled in subjects with fulminant CDI compared to
those with non-severe/severe disease. That said, no sizeable
difference was seen between the fulminant CDI subsets. On the
other hand, declining albumin values and increasing median
ATLAS scores mirrored disease worsening. The finding may help
better manage hypotensive CDI moving forward.
Speaking further, our study suggests that marked hypo-
albuminemia and elevated ATLAS scores in hypotensive CDI
patients may portend shock, ileus, or megacolon. Early miti-
gation efforts in CDI patients with shock, ileus, or megacolon
has been associated with improved outcomes [20]. Identifying
those at risk for critical illness and implementing precautionary
measures such as empiric intensive care unit (ICU) admission, a
lowered threshold for colectomy, and a greater willingness to
pursue fecal microbiota transplantation could prove beneficial.
Appreciating moderately elevated ATLAS scores in hypotensive
CDI patients may also better guide patient care. Receipt of
unrelated antimicrobials during CDI therapy is one component
of the ATLAS scoring system. Not uncommonly, broad-spectrum
empiric antibiotics are given to hypotensive CDI patients over
concerns of concomitant occult bacterial infection(s). Given
our findings, this may be worth reconsidering in persons with
already elevated ATLAS scores so to not further the risk of
shock, ileus, or megacolon.
While regression analysis found albumin values< 20 g/L and
ATLAS scores  6 to herald future shock, ileus, or megacolon,
the study population was modest - resulting in a relatively wide
confidence interval. This cautions against designating the fig-
ures as formal cutoffs. Two constraints were largely respon-
sible for paring our census. First, the 2018 relegation of













Age (years), mean (SD) 59.0 (15.7) 60.0 (14.7) 59.8 (14.5) 55.7 (19.2) 0.61
WBC (x 109 cells/litre), median (IQR) 10.0 (11.2) 7.4 (9.1) 14.0 (11.0) 14.9 (25.0) 0.04
Cr (umol/L), median (IQR) 114 (97) 106 (88) 124 (133) 133 (106) 0.63
Albumin (g/L), median (IQR) 25 (9) 26 (8) 24 (4) 18 (5) <0.0001
ATLAS score, median (IQR) 5 (3) 4 (3) 5 (3) 6 (1) <0.0001
CCI score, median (IQR) 4 (4) 4 (4) 5 (3) 4 (3) 0.69
Abbreviations: CCI, Charlson comorbidity index; Cr, creatinine; IQR, interquartile range; SD, standard deviation; WBC, white blood cell.
Table II
Odds ratios for predictors of fulminant CDI refractory to fluid
resuscitation
Variable OR (95% CI) aOR (95% CI)
Age 0.99 (0.96e1.02) d
WBC 1.08 (1.02e1.14) d
Creatinine 1.22 (0.83e1.80) d
Albumin < 20 g/L 4.63 (1.41e15.22) 3.91 (1.11e13.81)
ATLAS score  6 5.69 (1.86e17.42) 5.03 (1.58e16.01)
CCI score 1.09 (0.89e1.33) d
Abbreviations: aOR, adjusted odds ratio; CCI, Charlson comorbidity
index; CI, confidence interval; WBC, white blood cell.
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guidelines narrowed the recruitment interval. Second, the CDI
diagnostic testing method at UKMC changed from NAATalone to
multistep NAAT plus toxin in January 2018. Only patients who
underwent multistep testing were enrolled to avoid incorpo-
rating false positives. The decision strengthened internal val-
idity in exchange for reduced demographics. The recruitment
interval was further narrowed and suspected non-diagnosed
CDI patients (false negatives secondary to toxin EIA’s limited
sensitivity) were eliminated from consideration.
Additional limitations deserve mention. Characteristic CDI
symptoms were not personally confirmed in subjects given the
study’s retrospective nature. C. difficile colonized patients
may have unknowingly participated as a result. Targeted
measures were implemented to avoid this possibility, however.
Disease specific signs/symptoms i.e. acute diarrhea, ileus,
megacolon were verified in all patients via EMR review, and
exclusion criteria eliminated common alternative causes e.g.
laxative use, inflammatory bowel disease, prior colonic sur-
gery, etc. This aside, no subjects underwent NAP1/BI/027
molecular typing. Said testing is not routinely performed at
UKMC - reserved instead for epidemiological purposes. No
outbreaks occurred during the study period to warrant strain
typing. It is thus unclear if NAP1/BI/027 impacted our findings.
Conclusion
WBC counts, albumin values, and ATLAS scores differed in
CDI patients separated by severity. More importantly, declining
albumin values and increasing ATLAS scores mirrored disease
progression. Albumin values < 20 g/L and ATLAS scores  6
predicted ensuing shock, ileus, or megacolon in hypotensive
persons. While validated by regression analysis, our small study
population cautions against firmly utilizing these thresholds for
risk stratification. Future large-scale studies to explicitly
define inauspicious hypoalbuminemia, ATLAS scores are
encouraged.
Credit
Omar Ahmad: Conceptualization, Methodology, Inves-
tigation, Data Curation, Writing e Original Draft, Writing e
Review & Editing.
Timothy Crawford: Validation, Formal Analysis, Writing e
Original Draft.
Vaneet Arora: Software, Resources, Data Curation.
Mitu Maskey: Conceptualization, Supervision.
Acknowledgements





This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
References
[1] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC,
Coffin SE, et al. Clinical practice guidelines for Clostridium dif-
ficile infection in adults and children: 2017 update by the Infec-
tious Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA). Clin Infect Dis
2018;66:e1.
[2] Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S,
Turgeon N, et al. Host and pathogen factors for Clostridium dif-
ficile infection and colonization. N Engl J Med
2011;365:1693e703.
[3] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR,
et al. Burden of Clostridium difficile infection in the United
States. N Engl J Med 2015;372(9):825.
[4] Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval
of increased risk for Clostridium difficile infection after exposure
to antibiotics. J Antimicrob Chemother 2012;67:742e8.
[5] Gerding DN, File TM, McDonald LC. Diagnosis and treatment of
Clostridium difficile infection (CDI). Infect Dis Clin Pract (Baltim
Md) 2016;24(1):3e10.
[6] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC,
et al. Clinical practice guidelines for Clostridium difficile infec-
tion in adults: 2010 update by the society for healthcare epi-
demiology of America (SHEA) and the infectious diseases society
of America (IDSA). Infect Control Hosp Epidemiol
2010;31(5):431e55.
[7] Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL,
Schwartz MJ, et al. Prospective randomised trial of metronidazole
versus vancomycin for Clostridium-difficile-associated diarrhoea
and colitis. Lancet 1983;2:1043e6.
[8] Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-
Taber S, Fitts D, et al. Polymer alternative for CDI treatment
(PACT) investigators. Vancomycin, metronidazole, or tole-
vamer for Clostridium difficile infection: results from two
multinational, randomized, controlled trials. Clin Infect Dis
2014;59:345e54.
[9] Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of
vancomycin and metronidazole for the treatment of Clostridium
difficile-associated diarrhea, stratified by disease severity. Clin
Infect Dis 2007;45:302e7.
[10] Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W.
Comparison of vancomycin, teicoplanin, metronidazole, and
fusidic acid for the treatment of Clostridium difficile-associated
diarrhea. Clin Infect Dis 1996;22:813e8.
[11] Seltman AK. Surgical management of Clostridium difficile colitis.
Clin Colon Rectal Surg 2012;25(4):204e9.
[12] Patel UC, Wieczorkiewicz JT, Tuazon J. Evaluation of advanced
age as a risk factor for severe Clostridium difficile infection.
J Clin Gerontol Geriatr 2016;7:12e6.
[13] Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, et al. Clostri-
dium difficile ribotype does not predict severe infection. Clin
Infect Dis 2012;55(12):1661e8.
[14] Butt E, Foster JA, Keedwell E, Bell JE, Titball RW, Bhangu A,
et al. Derivation and validation of a simple, accurate and robust
prediction rule for risk of mortality in patients with Clostridium
difficile infection. BMC Infect Dis 2013;13:316.
[15] Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for
recurrence, complications and mortality in Clostridium difficile
infection: a systematic review. PLoS One 2014;9:e98400.
[16] Hernández-Garcı́a R, Garza-González E, Miller M, Arteaga-
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